XENE — Xenon Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.88bn
- $2.25bn
- 50
- 23
- 65
- 43
Annual cashflow statement for Xenon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | C2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.8 | -78.9 | -125 | -182 | -234 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 6.44 | 11.1 | 24.3 | 23.6 | 53.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -26.1 | -2.65 | -1.28 | 5.9 | 5.71 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -48.1 | -69.5 | -101 | -151 | -181 |
| Capital Expenditures | -2.64 | -2.05 | -2.89 | -5.62 | -3.08 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -14.2 | -245 | -291 | -106 | 168 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -16.8 | -247 | -293 | -111 | 165 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 85.8 | 448 | 278 | 354 | 12.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 20.3 | 131 | -118 | 91.4 | -5.93 |